Key Highlights

  • Global Health shares were trading at $0.05 during the 13 November 2026 session, up 11.11%.
  • Operating cash outflow improved by $237,000, or 22%, in the September 2026 quarter.
  • Twelve-month operating cash outflow fell 57% to $553,000, and group Cash Flow improved by 71%.

During the Trading session on 13 November 2026, Global Health Ltd (ASX:GLH) shares were trading at $0.05, up 11.11%, while the S&P/ASX 200 was down 0.73% at 9,079.70 at 12:39 pm AEDT. Global Health sells software to healthcare customers on recurring licence subscriptions, with implementation fees charged for new deployments. Its latest update was its Appendix 4C cash flow report and quarterly Business activity report for the quarter ended 30 September 2026, released on 26 October 2026.

Operating cash flow improvement

Operating cash outflow improved by $237,000, or 22%, from $1.065 million in the September 2025 quarter to $828,000 in the September 2026 quarter. Figures are in Australian dollars and are subject to audit. The company said it increases sales and Marketing activity in the first half of the financial year, as prospects typically begin procurement in the first quarter of the new year.

Twelve-month cash flow trends

For the twelve months to September 2026, operating cash outflow was $553,000, a 57% reduction of $738,000 on the prior twelve months. Group cash outflow for the same period was $296,000, a 71% reduction of $713,000. Staff and contractor expenses for the twelve months fell by $739,000 over the same comparison.

Customer billing and deal timing

Customers can pay recurring subscriptions monthly, quarterly, half-yearly or annually in advance. Implementation fees are invoiced partly on order, with the balance due when implementation services are completed before go-live. Decisions on major deals are typically made in the December and March quarters, with large projects going live between May and November.

Sector context

Software providers selling into healthcare organisations often face long sales cycles and procurement approvals, which can cause Revenue to be recognised unevenly across the year. Subscription models can provide steadier income once contracts are in place, but growth depends on winning new customers and completing implementations on schedule.

Risks investors are watching

The company remains cash flow negative on both operating and group measures, and the improvement in outflows is relative to prior periods. Its results depend on the timing of major deal decisions and go-live dates, which can shift between quarters. Competition in healthcare software and the need to fund sales activity in the first half of the year are also relevant to the outlook.

What to watch ahead

Investors will look for deal announcements following the December and March quarter decision periods, and for the next quarterly cash flow figures. Progress on implementations scheduled to go live between May and November will also be followed.

Final Word

Global Health's latest report shows a narrower cash outflow over both the quarter and the year. Its next updates will show whether new contracts and go-live milestones support further improvement.